News

Primary results presented at ASN Kidney Week 2023 showed spironolactone missed the trial's primary endpoint.

The 2-year data from the PROTECT study confirms the sustained benefit of sparsentan in patients with IgA nephropathy.

Aldosterone synthase inhibition dose-dependently reduced albuminuria by up to 40% in participants with CKD, according to study results presented at ASN Kidney Week 2023.

Although the DUPLEX trial missed its primary endpoint of eGFR slope in patients with FSGS, results point to greater reductions in proteinuria and in risk of kidney failure with sparsentan use relative to irbesartan—making its case for becoming a standard of care for the glomerular disease.

Stacie Bell, PhD, discusses the partnership between Lupus Therapeutics and AbbVie for the phase 3 clinical program of upadacitinib in patients with SLE, emphasizing the importance of collaboration and their role in accelerating the study process, recruitment, and the potential for meaningful advancements in lupus treatment.

A post hoc analysis of the phase 3 YOSEMITE and RHINE trials found significantly more patients had leakage resolution with faricmab than with aflibercept at Week 16.

In this segment of his interview, Dr. Chovatiya discussed some of the key safety data on secukinumab following the drug’s FDA approval for hidradenitis suppurativa.

Data presented at ASN Kidney Week 2023 described the effects of SGLT2 inhibition in young patients with Alport syndrome.

Results from the phase 3 YOSEMITE and RHINE trials show more than half of faricimab treat-and-extend patients met the criteria for a potential every-20-week dosing extension.

An analysis of Target-HTN provides new insight into the effects of lorundrostat among patients with uncontrolled or treatment-resistant hypertension.

Results presented at ASN Kidney Week 2023 highlighted the efficacy of twice weekly hemodialysis.

A subgroup analysis of hemodialysis patients treated with cognitive behavioral therapy for insomnia was presented at ASN Kidney Week 2023.

An analysis of the MIRROR trial from ASN Kidney Week 2023 details the effects of urate-lowering therapy on blood pressure among patients with uncontrolled gout receiving pegloticase plus methotrexate in the phase 4 trial.

Rajiv Agarwal, MD, MS, provides insight into an analysis from ASN Kidney Week 2023 detailing the effect of early albuminuria reduction on risk of adverse kidney and cardiovascular outcomes in people with T2D and chronic kidney disease.

Presented at ASN Kidney Week 2023, results of the ENVISION trial provide the latest insight into effects of sibeprenlimab in management of IgA nephropathy as the nephrology community awaits the results of its ongoing phase 3 trial.

Our gastroenterology month in review highlights multiple FDA approvals, conference coverage from ACG 2023, and other top news in gastroenterology.

In our October 2023 endocrinology month in review, our editorial team highlights regulatory updates, pipeline news, and conference data capturing the attention of the field during the month.

John W. Ostrominski, MD, describes the prevalence and overlap of cardiac, renal, and metabolic conditions in US adults over a 20-year period.

VOQUENZA® provides quicker healing than Lansoprazole, according to an FDA-approved Phase 3 study

In this interview, Dr. Chovatiya responds to questions about the new FDA approval of secukinumab for patients with hidradenitis suppurativa.

Rosalind Ramsey-Goldman, MD, discusses her study, “The impact of US abortion policy on rheumatology clinical practice: a cross-sectional survey of rheumatologists.”

This new research sheds light on the importance of follow-up meetings for young patients discharged from emergency departments.

V Michael Holers, MD, discusses the creation of Rheumatology Lab in response to a pressing need within the clinical practice community to provide an easily accessible resource for physicians to guide patients to valuable information.

Patients with progressive DKD had greater gastrointestinal symptom scores than those with stable DKD.

Our October 2023 hepatology month in review features phase 2/3 data, updates in the hepatology pipeline, and other top news.

In this episode, hosts discuss the FDA clearance of the Omnipod 5 App for iPhones and a pair of studies examining use of automated insulin delivery systems.

Adults with ADHD have greater reduction of symptoms with regulatory licensed doses of stimulants than unlicensed doses.

Secukinumab (Cosentyx) becomes the first IL-17A inhibitor, as well as the first drug since 2015, approved to treat adults with moderate to severe HS.

This segment of Dr. Kwatra’s latest interview featured a discussion on the future of prurigo nodularis treatment and the implications of his team’s research.

The FDA announced the approval of ustekinumab-auub (Wezlana) as a biosimilar and interchangeable to ustekinumab (Stelara) for a half dozen inflammatory conditions on October 31, 2023.